Free Trial

Halozyme Therapeutics (HALO) Stock Forecast & Price Target

$51.55
+0.69 (+1.36%)
(As of 06/21/2024 ET)

Halozyme Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$54.13
5.00% Upside
High Forecast$71.00
Average Forecast$54.13
Low Forecast$40.00
TypeCurrent Forecast
6/23/23 to 6/22/24
1 Month Ago
5/24/23 to 5/23/24
3 Months Ago
3/25/23 to 3/24/24
1 Year Ago
6/23/22 to 6/23/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
5 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
Hold
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$54.13$53.14$53.88$54.78
Forecasted Upside5.00% Upside32.00% Upside46.77% Upside27.65% Upside
Get Halozyme Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

HALO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HALO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Halozyme Therapeutics Stock vs. The Competition

TypeHalozyme TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.70
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside5.00% Upside898.48% Upside10.92% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/7/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$48.00 ➝ $58.00+12.75%
6/7/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$48.00 ➝ $51.00-0.86%
6/4/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00+10.99%
5/8/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Outperform ➝ Market Outperform$72.00 ➝ $71.00+67.18%
4/16/2024Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$50.00+30.01%
2/29/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$54.00+36.05%
1/18/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$45.00 ➝ $40.00+10.99%
12/26/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$61.00 ➝ $59.00+57.08%
3/27/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$58.00+68.16%
3/16/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$42.00+16.44%
3/16/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$42.00+4.87%
2/23/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$54.00 ➝ $52.00+1.54%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 02:57 PM ET.

HALO Forecast - Frequently Asked Questions

What is Halozyme Therapeutics's stock forecast and purchase recommendation?

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Halozyme Therapeutics is $54.13, with a high forecast of $71.00 and a low forecast of $40.00. The consensus rating for Halozyme Therapeutics stock is Moderate Buy based on the current 2 hold ratings and 6 buy ratings for HALO. Learn more on HALO's analyst rating history.

Do Wall Street analysts like Halozyme Therapeutics more than its competitors?

Analysts like Halozyme Therapeutics more than other "medical" companies. The consensus rating score for Halozyme Therapeutics is 2.75 while the average consensus rating score for "medical" companies is 2.70. Learn more on how HALO compares to other companies.

Is Halozyme Therapeutics being downgraded by Wall Street analysts?

Over the previous 90 days, Halozyme Therapeutics's stock had 1 downgrade by analysts.

Does Halozyme Therapeutics's stock price have much upside?

According to analysts, Halozyme Therapeutics's stock has a predicted upside of 26.55% based on their 12-month stock forecasts.

What analysts cover Halozyme Therapeutics?

Halozyme Therapeutics has been rated by research analysts at Benchmark, HC Wainwright, JMP Securities, Piper Sandler, and Wells Fargo & Company in the past 90 days.


Stock Forecasts and Research Tools

This page (NASDAQ:HALO) was last updated on 6/22/2024 by MarketBeat.com Staff

From Our Partners